Op-ed warns Florida will absorb fallout from federal peptide compounding policy
The piece urges state regulators to demand formal rulemaking rather than an enforcement-discretion policy covering BPC-157 and other wellness peptides.
DO
By Daniel Okafor · Regulatory Correspondent
Oct 23 09:57 ETSource: Tampa Free Press
The wire
- 01HHS and FDA sent an Interim Access Policy for Compounding Using Certain Peptides to the White House Office of Management and Budget on Oct. 14, which the author describes as a promise not to enforce rather than an approval.
- 02FDA staff briefing documents released June 29 recommended against adding BPC-157, KPV, TB-500, MOTS-c, emideltide, Semax or Epitalon to the 503A bulks list, citing impurities, immunogenicity risk and limited human data.
- 03The author calls on Florida's congressional delegation, attorney general, Board of Pharmacy and Legislature to act; this is commentary, and the interim policy's final terms have not been published.
From the source
Read at tampafp.comOp-Ed: Florida Will Pay For Washington’s Peptide Shortcut
The administration’s plan to let pharmacies compound unproven peptides would land hardest in the Sunshine State, which has fewer safeguards in place than its lawmakers seem to think. Florida’s leaders should insist on the front door.
